Cambridge University Press 978-1-108-41059-5 — Autism and Pervasive Developmental Disorders Edited by Fred R
Total Page:16
File Type:pdf, Size:1020Kb
Cambridge University Press 978-1-108-41059-5 — Autism and Pervasive Developmental Disorders Edited by Fred R. Volkmar Index More Information Index AAC, see alternative follow-up/outcome studies APA, see American Psychiatric communication in adulthood, 225 Association (APA) strategies (AAC) future directions, 238–40 applied behavior analysis AAP, see American Academy quality of life and mental (ABA), 197 of Pediatrics (AAP) health, 231–8 growth in United States, 199 ABA, see applied behavior trajectories of development multi-state program to ASD analysis (ABA) from childhood to insurance, 210–12 ABC Hyperactivity subscale adulthood, 226–30 applied research, 193 (ABC-H subscale), advocacy, 192, 195, 198, 204, ARBD, see Alcohol-Related 164–5 210, 212–13, 215 Birth Defects (ARBD) ABC Social Withdrawal sub- AEDs, see Antiepileptic drugs aripiprazole, 159–60 scale (ABC-SW), 167 (AEDs) ARND, see Alcohol-Related Aberrant Behavior Checklist– afective disorders, 232 Neurodevelopmental Irritability subscale Afordable Care Act (ACA), Disorder (ARND) (ABC-I subscale), 159 198, 211 articulation development, 94 ACA, see Afordable Care Act AFIRM, see Autism Focused AS, see Asperger syndrome (ACA) Intervention (AS) adaptive behavior, 65–7, 179, Resources and ASD, see autism spectrum 228 Modules (AFIRM) disorder (ASD) impairments, 67 age-appropriate language ASHA, see American Speech- informant ratings of work- forms, 98 Language- Hearing ing memory, 64 AIR-B, see Autism Association (ASHA) patterns of change in, 226 Intervention Research Asperger syndrome (AS), 93, adaptive functioning, 17, 143, Network on Behavioral 98–9, 141–2, 231–2 224, 226 Health (AIR-B) Asperger’s disorder (AspD), 8, ADDM Network, see Autism AIR-P, see Autism Intervention 9, 14–15, 26, 144 and Developmental Research Network on assessment Disabilities Monitoring Physical Health (AIR-P) assessment-to-intervention Network (ADDM Net- Alcohol-Related Birth Defects process, 176 work) (ARBD), 135 with children and youth ADHD, see attention-deicit/ Alcohol-Related Neurode- with ASD, 178–9 hyperactivity disorder velopmental Disorder communication, 100–3 (ADHD) (ARND), 135 practices, 194–5 ADI-R, see Autism Diagnostic alternative therapies, 237–8 ATN, see Autism Speaks Interview-Revised American Academy of Pediatrics Autism Treatment (ADI-R) (AAP), 195, 206 Network (ATN) adolescence, 234 American Psychiatric Associa- atomoxetine, 165 ADOS, see Autism Diagnostic tion (APA), 4, 133–4 attachment, 70, 167 Observation Schedule American Speech- Language- attention in ASD, 62 (ADOS) Hearing Association alerting component of, 62–3 adulthood, follow-up/ (ASHA), 93 executive component of, 63 outcome studies in, ANT, see Attention Network orienting component of, 63 225 Task (ANT) Attention Network Task adults with ASD antiepileptic agent valproic (ANT), 62 adult outcomes, 220 acid, 135 attention-deicit/hyperactivity 1960–70, 220–1 antiepileptic drugs (AEDs), 163 disorder (ADHD), 14, 1980–90, 222 antiepileptics, 163 43, 64, 117, 129–30, 2000–017, 222–5 anxiety, 116, 158, 166 158, 164–5, 207 249 © in this web service Cambridge University Press www.cambridge.org Cambridge University Press 978-1-108-41059-5 — Autism and Pervasive Developmental Disorders Edited by Fred R. Volkmar Index More Information 250 Index atypical autism, 26, 35 autism-associated medical brain–behavior mechanisms, atypical personality syndrome, 137 129 development, 6, 9 autistic, 4 BRIEF, see Behavior Rating Autism and Developmental features, 129–30 Inventory of Executive Disabilities Monitor- psychopathy, 44 Function (BRIEF) ing Network (ADDM traits, 136–7 broader autism phenotype Network), 36, 195, 212 autopsy studies in autism, 141 (BAP), 9, 14–15, 113, Autism Biomarkers autosomal gene, 118 132–3, 235 Consortium for Clinical buspirone, 166 Trials (ABC-CT), 17 BAP, see broader autism Autism Diagnostic phenotype (BAP) CAA, see Combating Autism Interview-Revised Basic Research, 193–4, 196 Act (CAA) (ADI-R), 11, 28 BCBA, see Board Certiied candidate genes, 116, 130–1 Autism Diagnostic Observa- Behavior Analyst CARES Act, 204 tion Schedule (ADOS), (BCBA) Catechol-O-methyltransfer- 28, 143 Behavior Rating Inventory of ase, 139–40 ADOS-2, 11–12 Executive Function categorical diagnostic Autism Focused Intervention (BRIEF), 146 approaches of autism, 4 Resources and Modules behavioral analysis, 177 DSM-III, 4–6 (AFIRM), 180 behavioral interventions, 176, DSM-III-R, 6–7 Autism Intervention 179 DSM-IV and ICD-10, 7–9 Research Network comprehensive treatment DSM-5, 9–11 on Behavioral Health model, 180–2 CBT, see cognitive behavior (AIR-B), 205 controversial interventions, therapy (CBT) Autism Intervention Research 185–6 CDC, see Centers for Disease Network on Physical educational settings, 182–3 Control and Preven- Health (AIR-P), 205 evidence-based practice, tion (CDC) Autism Speaks Autism 179 Center on Secondary Educa- Treatment Network focused intervention tion for Students with (ATN), 205 practices, 179–80 Disabilities (CSESA), autism spectrum disorder intervention themes across 182, 185 (ASD), 1, 4, 11, 13, 25, lifespan, 183–5 Centers for Disease Control 61, 89, 113, 129, 158, intervention/educational and Prevention (CDC), 176, 191, 196, 220 process, 177–9 26, 28, 41, 195 communication deicits, service landscape, 176–7 ADDM Network, 37, 44, 48 89–90 University of North Carolina central coherence, 61, 145 correlates in epidemiological at Chapel Hill, 176 cerebral palsy, 129–30 surveys, 44 behavioral patterns, 70 cerebrospinal luid (CSF), 139 genetics, 115–19 behavioral phenotype childhood older non-speakers with, syndrome (BPS), 130 onset psychosis, 112 99–100 behavioral therapy schizophrenia, 3, 4 prevalence, 47 approaches, 158 severity of ASD symptoms prevalence estimates for behaviorist techniques, 103 in, 229 combined ASDs since biallelic gene, 118 Childhood Disintegrative 2000s, 36–7 biological markers, 16–17 Disorder, 8 quality of life and mental biological mechanisms, Childhood Onset PDD health in adults with, 113–14 (COPDD), 6, 9 231–8 biological pathways, 131–2 childhood to adulthood, recover, 227 birth cohorts, 42–3 trajectories of severity of ASD symptoms Board Certiied Behavior development from, 226 in childhood, 229 Analyst (BCBA), 178, adaptive functioning, 226 signs, 91 197 ASD “recover”, 227 symptoms severity in “Bookish”, 98 autism symptomatology, childhood, 229 BPS, see Behavioral phenotype 226–7 unspeciied ASDs in earlier syndrome (BPS) cognitive and language surveys, 35 brain-based disorder, 3 abilities in, 228 © in this web service Cambridge University Press www.cambridge.org Cambridge University Press 978-1-108-41059-5 — Autism and Pervasive Developmental Disorders Edited by Fred R. Volkmar Index More Information Index 251 cognitive functioning, 226 communication, see also language DA, see dopamine (DA) factors relating to adult assessment, 100–2 DBH, see dopamine-(3- outcomes, 227 deiciencies, 89 hydroxylase) (DBH) family and social inluences, deicits, 89–90, 97 DCD, see developmental 230 communication and develop- coordination disorder gender, 229–30 ment in ASD (DCD) medical and psychiatric assessing communication, DCS, see D-cycloserine (DCS) comorbidities, 230 100–3 D-cycloserine (DCS), 168 severity of ASD symptoms domains, 89 DD, see developmental delay in, 229 irst year of life, 90–1 (DD) children, 91, 93–4 intervention for de novo mutation, 131, 132 Children’s Yale Brown Obses- communication, 103 de novo variant, 117 sive Compulsive Scale later language development, declarative memory, 67, 68 (CY-BOCS), 165–6 97–9 7-dehydrocholesterol, 137 cholesterol, 137 older non-speakers with Department of Education, 40 cholesterol-steroid ASD, 99–100 developmental coordination contributions, 146–7 pragmatic checklist, 102 disorder (DCD), 130 cholesterol-steroid hormone preschool development, 93–7 developmental delay (DD), pathways and autism, toddler years, 91–3 131 138–9 community-based care, 224 developmental regression, 9 chromatin remodeling, 131–2 comorbidity, 129 diabetes, 121 chromosome microarray compensation, 67 diagnosis, of autism, 1–3 (CMA), 114–15 comprehension skills, 92, categorical diagnostic chromosomes, 130–1 97–8, 100 approaches, 4–11 citalopram, 165–6 comprehensive treatment developments of autism, clinical childhood cases of model (CTM), 179–82 14–17 autism, 129 consanguineous families, 118 diagnostic challenges, clinical utility, 119–21 content, language, 90 13–14 clonidine, 162, 167 features, 94 diagnostic instruments, clozapine, 161 controversial interventions, 11–13 Clozapine Risk Evaluation and 185–6 diagnostic odyssey, 120 Mitigation Strategy conversational context, 98 diagnostic overshadowing, (Clozapine REMS), COPDD, see Childhood Onset 14 161 PDD (COPDD) diagnostic substitution, 45 CMA, see chromosome copy number variations/variants diference in approaches to microarray (CMA) (CNVs), 114–15, 130–1 and challenges, 4 CMV infection, see cytomeg- core social impairment, 167–8 level autism, 129–30 alovirus infection cortisol, 138 new developments, 16–17 (CMV infection) CROSS-sectional variability Diagnostic and Statistical CNVs, see copy number in epidemiological Manual of Mental variations/variants surveys, 40–2 Disorders (DSM), 4, (CNVs) CSESA, see Center on 65, 112 cognitive behavior therapy Secondary Education DSM-III, 3, 4–6, 26 (CBT), 207 for Students with DSM-III-R, 6–7 cognitive/cognition Disabilities (CSESA) of “residual” infantile abilities in childhood, 228 CSF, see cerebrospinal luid autism, 6 behavior, 65–7 (CSF) DSM-IV, 7–9 lexibility, 15 CTM, see comprehensive treat-